David Dunn, Professor of Medical Statistics
David joined the Unit in 1998 after previous spells at London School of Hygiene and Tropical Medicine and the Institute of Child Health. In 1997 he gained a PhD on statistical aspects around the vertical transmission of HIV infection.
His main current research interests are HIV prevention, HIV drug resistance, the collection/analysis of safety data, and the statistical classification of RCTs. He was the trial statistician on the PROUD trial, a pragmatic RCT to assess the effectiveness of pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission among gay men in the UK. The results of this study provided a major impetus to the provision of PrEP in the UK and internationally. David is also collaborating with Professor Dave Glidden (UCSF) on challenges in the design of future PrEP trials, in the context of a highly effective established regimen.
Dunn DT, Glidden DV, Stirrup OT, McCormack S. The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents. Lancet HIV. 2018; 5:e329-e334.
Dunn DT, Copas AJ, Brocklehurst P. Superiority and non-inferiority: two sides of the same coin? Trials. 2018;19(1):499
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387:53-60.
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D, Dunn DT. No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom. J Infect Dis 2016; 214:1302-1308.
Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Scott K, Dunn DT; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV 2015; 2(10):e417-26